FDA Approved: NEXLIZET — Supplemental Application (Esperion Therapeutics, Inc.)

View source ↗

Summary

FDA approved a supplemental application for NEXLIZET (bempedoic acid and ezetimibe) to update/expand its labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Heterozygous Familial Hypercholesterolemia
• Hyperlipidemia

Drugs mentioned

• NEXLIZET (bempedoic acid and ezetimibe)

Snippet

SUPPL AP for NEXLIZET (BEMPEDOIC ACID AND EZETIMIBE)